FLAGYSTATIN 500 MG — DIN 01926837
METRONIDAZOLE : 500 MG NYSTATIN : 100000 UNIT · AVENTIS PHARMA INC · SUPPOSITORY · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is FLAGYSTATIN?
FLAGYSTATIN 500 MG contains METRONIDAZOLE : 500 MG NYSTATIN : 100000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 01926837, held by AVENTIS PHARMA INC, supplied as SUPPOSITORY for VAGINAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-2004. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is FLAGYSTATIN used for?
Mixed vaginal infection due to Trichomonas vaginalis and Candida albicans.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Nystatin, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Nystatin, Combinations, across 3 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI-AVENTIS CANADA INC | 2 | 1 | FLAGYSTATIN | Sourceable in Canada |
| AVENTIS PHARMA INC | 1 | 0 | FLAGYSTATIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | SUPPOSITORY |
| Route | VAGINAL |
| Pack configuration (monograph) | Boxes of 10 ovules with applicator. |
| Storage | Store at room temperature between 15 - 25ºC and protect from light. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Nystatin, Combinations |
|---|---|
| ATC code | G01AA51 |
| AHFS class | 84:04.08.28 ; 84:04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01926837 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1926837 |
| Brand name | FLAGYSTATIN |
| Generic / active ingredient | METRONIDAZOLE : 500 MG NYSTATIN : 100000 UNIT |
| Market authorization holder | AVENTIS PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | G01AA51 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G01AA |
| Current status | CANCELLED POST MARKET |
| Status date | 30-Jul-2004 |
| Original market date | 1972-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One vaginal ovule daily, inserted deep into the vagina, for 10 consecutive days. A second 10-day course may be given if cure is not achieved.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to metronidazole, nystatin, or imidazoles. Combined oral metronidazole avoided in active neurological disorders, blood dyscrasia, hypothyroidism, or hypoadrenalism.
Warnings and precautions
Metronidazole is carcinogenic in rodents. Risk of severe hepatotoxicity in Cockayne syndrome. Potential for peripheral/central neuropathy. May impair condoms/diaphragms.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FLAGYSTATIN | 100000 UNIT | OVULE | SANOFI-AVENTIS CANADA INC | MARKETED | 01926829 |
| FLAGYSTATIN | 100000 UNIT / 4.5 G | CREAM | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 01926845 |
2 · Same class — other molecules in ATC G01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nystatin | MESTATIN · MYCOSTATIN VAGINAL CRM 25000UNIT · NADOSTINE TAB 100000UNIT · NILSTAT 25000UNITS/G · +5 more | 9 | 1 | Yes |
| Nystatin, Combinations | FLAGYSTATIN | 3 | 1 | Yes |
| Clindamycin | DALACIN VAGINAL CREAM | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G01AF | Butoconazole · Clotrimazole · Econazole · Metronidazole · Miconazole · +1 more | 62 | 26 |
| G01AC | Clioquinol, Combinations · Dequalinium · Diiodohydroxyquinoline, Combinations · Oxyquinoline | 5 | 1 |
| G01AG | Terconazole | 5 | 1 |
| G01AE | Combinations Of Sulfonamides · Sulfonamides | 2 | 0 |
| G01AX | Other Antiinfectives And Antiseptics · Povidone-Iodine | 8 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.